SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

PSMA PET prognosis, PROMISE registry, PSMA PET survival prediction, prostate cancer prognostic biomarker, PSMA PET risk stratification, Emerging Prognostic Value of Molecular Imaging in Prostate ...

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

Philipp Backhaus presented first-in-human data on [⁶⁸Ga]Ga-OncoACP3-DOTA PET imaging, targeting prostatic acid phosphatase (ACP3), a novel and promising theranostic marker for prostate cancer.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

Interdisciplinary GU Cancer Forum 2025, non muscle invasive bladder cancer (NMIBC), Novel Agents in NMIBC, EV-104 trial, SunRISe bladder trials, TAR-200, BOND-003 trial, CREST Trial, sasanlimab, ...

SNMMI 2025 phase I trial of 61Cu-NODAGA-PSMA I&T for prostate cancer patients, prostate PET imaging, 68Ga-PSMA-11, 18F-Piflulolastat (Pylarify), and 18F-Flotufolastat (Posluma), NODAGA-PSMA I&T.

SNMMI 2025 novel PSMA-targeting drug 177Lu-P17-088, metastatic castration-resistant prostate cancer (mCRPC), VISION and PSMAfore trials, PCWG3 guidelines.

ASCO 2025, clear cell renal cell carcinoma (ccRCC), STARLITE-1 trial, 177Lu girentuximab, cabozantinib, nivolumab, 177Lu girentuximab plus cabozantinib and nivolumab, cGAS-STING pathway.

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.